Education
About Us
Working with TipRanks
Follow Us
Zomedica Pharma (ZOM)
:ZOM
ZOM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.09 - $0.20
Previous CloseN/A
Volume6.59M
Average Volume (3M)3.79M
Market Cap
$95.35M
Enterprise Value$59.65M
Total Cash (Recent Filing)$12.95M
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Mar 13, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding979,949,650
10 Day Avg. Volume4,315,455
30 Day Avg. Volume3,789,877
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.57
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.44
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$0.25Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Zomedica Pharmaceuticals News
PremiumCompany Announcements
Zomedica Transitions to OTCQB Market Following NYSE Delisting
PremiumCompany Announcements
Zomedica Appoints New CFO to Drive Growth
PremiumCompany Announcements
Zomedica’s Revenue Up 10% Amid Global Expansion
PremiumCompany Announcements
Zomedica Corp Posts Increased Revenue Amid Loss
---
Ownership Overview
1.74% Insiders
5.84% Mutual Funds
0.48% Other Institutional Investors
87.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ZOM FAQ
What was Zomedica Pharma’s price range in the past 12 months?
Zomedica Pharma lowest stock price was $0.09 and its highest was $0.20 in the past 12 months.
What is Zomedica Pharma’s market cap?
Zomedica Pharma’s market cap is $95.35M.
When is Zomedica Pharma’s upcoming earnings report date?
Zomedica Pharma’s upcoming earnings report date is Mar 13, 2025 which is 22 days ago.
How were Zomedica Pharma’s earnings last quarter?
Zomedica Pharma released its earnings results on Nov 07, 2024. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
Is Zomedica Pharma overvalued?
According to Wall Street analysts Zomedica Pharma’s price is currently Undervalued.
Does Zomedica Pharma pay dividends?
Zomedica Pharma does not currently pay dividends.
What is Zomedica Pharma’s EPS estimate?
Zomedica Pharma’s EPS estimate is >-0.01.
How many shares outstanding does Zomedica Pharma have?
Zomedica Pharma has 979,949,650 shares outstanding.
What happened to Zomedica Pharma’s price movement after its last earnings report?
Zomedica Pharma reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zomedica Pharma?
Currently, no hedge funds are holding shares in ZOM
---
Zomedica Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.25 (400.00% Upside)
$0.25 (400.00% Upside)
Blogger Sentiment
Bullish
ZOM Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $18.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.71%
12-Months-Change
Fundamentals
Return on Equity
-26.82%
Trailing 12-Months
Asset Growth
-22.15%
Trailing 12-Months
Company Description
Zomedica Pharma
Zomedica Pharmaceuticals Corp. operates as a development stage veterinary diagnostic and pharmaceutical company. It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. The company was founded by Gerald L. Solensky, Jr. on January 7, 2013 and is headquartered in Ann Arbor, MI.
---
ZOM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected strong revenue growth and successful global expansion initiatives, with improvements in cost management and financial health. However, the increased net loss, challenges in Assisi sales, and potential delisting risk present concerns moving forward.Read More>---
ZOM Stock 12 Month Forecast
Average Price Target
$0.25
▲(400.00% Upside)
Technical Analysis
Idexx Laboratories
―
Petmed Express
―
Zoetis
―
Hepion Pharmaceuticals
―
Elanco Animal Health
―
Best Analysts Covering ZOM
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-67.75%
reiterated a buy rating 2 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -67.75% per trade.
---